Reported Saturday, Pfizer's Berobenatide Achieves 15.9% Weight Loss At 32 Weeks With No Plateau In VESPER-1 As Monthly GLP-1 Phase 3 Program Advances

뉴스 본문을 불러오고 있어요.

Reported Saturday, Pfizer's Berobenatide Achieves 15.9% Weight Loss At 32 Weeks With No Plateau In VESPER-1 As Monthly GLP-1 Phase 3 Program Advances | 웨이프 WAPE

Reported Saturday, Pfizer's Berobenatide Achieves 15.9% Weight Loss At 32 Weeks With No Plateau In VESPER-1 As Monthly GLP-1 Phase 3 Program Advances

기사 요약

관련 종목

댓글 —